High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival - Final Results of the CELSG Phase III CML11 "IST

Perzeri, Andreas L; ...; Bogdanovic, Andrija D; ...; (broj, koautora 20)

Rezultati

eNauka > Results > High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival - Final Results of the CELSG Phase III CML11 "IST

Naziv:	High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival - Final Results of the CELSG Phase III CML11 "IST
Autori:	Perzeri, Andreas L; ...; Bogdanovic, Andrija D ; ...; (broj, koautora 20)
Godina:	2010
Publikacija:	BLOOD
ISSN:	0006-4971 Blood Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 116 br. 21 str. 934-935
WoS-ID:	000289662202494
URI:	https://enauka.gov.rs/handle/123456789/799715
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.